To determine the effect of race on cardiovascular disease occurrence among treated hypertensive patients, the experience of 1,807 black and 2,962 white hypertensive patients who entered a union/management-sponsored, worksite-based treatment program (1973)(1974)(1975)(1976)(1977)(1978)(1979)(1980)(1981)(1982)(1983)(1984)(1985), was evaluated. Participants had similar socioeconomic profiles, equal access to health benefits, and received standard treatment. Median duration of observation was 42 months. Blacks had 48, and whites 129, of the 177 morbid (strokes and heart attacks) or mortal cardiovascular disease outcomes. At baseline, blacks had more electrocardiographic abnormalities (32% vs. 19%, p< 0.0001), lower mean cholesterol (218 vs. 230 mg%,p< 0.001), smoked more (35% vs. 30%, p< 0.001), and were less likely to be treated for hypertension before entering the program (53% vs. 58%, /7<0.01) than whites. They were also more likely than whites to belong to unions employing less skilled workers (/?<0.0001). Overall, all-cause mortality rates between the races were similar. However, total cardiovascular disease morbidity and mortality rates were 10.5 (whites) and 6.4 (blacks) per 1,000 person years (p<0.005); the difference was largely explained by higher myocardial infarction rates among older (55 years or older) white men (15.6 vs. 7.5, /><0.05). That advantage was not present amongst younger black persons. In fact, blacks lost more years of life before age 65 (102 vs. 64 years/1,000 persons, p<0.025). In a Cox proportional hazards regression analysis, an interaction term of age and race, gender, baseline smoking status, prior treatment status, and electrocardiogram abnormality were strongly predictive of cardiovascular disease morbidity and mortality. Prior history of cardiovascular disease, cholesterol, and body mass index were less significant predictors, but union status was not. These findings, while reflecting the special concern of risk of cardiovascular disease for young blacks, suggested that, at similar starting blood pressure levels, blacks, when given equal access to the same treatment, will achieve similar, overall blood pressure declines and experience a lower incidence of cardiovascular disease than whites. (Hypertension 1989; 14:227-234) O verall, cardiovascular disease (CVD) in the United States has a disproportionately greater effect on blacks than whites, although for persons over 65 years old, CVD mortality among whites begins to exceed that of blacks.
O verall, cardiovascular disease (CVD) in the
United States has a disproportionately greater effect on blacks than whites, although for persons over 65 years old, CVD mortality among whites begins to exceed that of blacks. 1 A variety of economic, social, behavioral, medical care, or health factors may explain these differences.
Among health factors frequently cited to account for the observed racial differences is high blood pressure (BP). 3 Its greater prevalence among American blacks as opposed to whites almost certainly contributes to their higher CVD mortality. 4 - 5 It has also been suggested that the differential impact of a given level of BP or its control among blacks may account for their adverse experience. 6 Specifically, it has been postulated that blacks may, at the same BP level, suffer greater harm than do whites. 7 It has also been suggested that response to therapy, for a variety of reasons, may be less satisfactory for blacks. 8 -9 In the context of a union/management-sponsored, occupationally based BP control program, 10 
-

11 it has been possible to examine these issues relatively free of important confounding influences. Under these circumstances, care is provided equally to all eligible workers according to a systematic protocol and without direct cost to the patient. Thus, issues of access or differences in quality of care should not influence the observed outcomes. Since patients are all members of a unionized work force, socioeconomic differences are also minimized to a considerable extent. It has therefore been possible, in the absence of extraneous factors that frequently interfere with black/ white comparisons, to examine the course and outcome of treatment for patients in a multiracial BP control program. This report describes BP response to therapy as well as cardiovascular morbidity and mortality of both black and white treated hypertensive patients.
Patients and Methods
Data Sources
The study cohort consisted of 1,807 black and 2,962 white employees who entered a worksitebased, union-sponsored hypertension control program between 1973 and 1985. 10 n This prepaid program is part of the health benefits package for members of participating unions and provides screening and management of hypertension with a systematic, stepped-care approach at convenient locations. The BP criteria for participation were: diastolic (DBP) 95 mm Hg or greater, systolic (SBP) 160 mm Hg or greater on at least three occasions, or current pharmacological treatment for hypertension regardless of BP level. 10 Uniformly obtained baseline information included demographic characteristics, hypertension treatment status, smoking, CVD history, physical evaluation, and clinical chemistry measurements. Data available at each revisit included sitting BP, drug status, and intervening hospitalizations for any condition. 11 In addition, annual physical examinations (including an electrocardiogram [ECG] and blood chemistry) were performed by the program physician.
A surveillance system was set up to detect morbid and mortal events that occurred during program participation. The clinic nurse systematically monitored reports by patients, friends, or family members of the occurrence of any hospitalization or death. Hospital and medical charts were sought for review, supplemented by death certificates when appropriate. The research staff was notified, would maintain a check on requests made or received, and periodically, would update new or corrected information on a computerized data base. The nurse and research staff would follow up patients who have missed appointments to determine whether an illness or death had occurred. Each union also made available morbidity and mortality records collected for insurance purposes. Of concern to the study was whether such events occurred within 6 months after a patient had left the program.
Morbid and mortal events were classified using the International Classification of Diseases Manual, 9th Revision. For this study, morbid events of interest included only cases of myocardial infarction (MI) (ICD code 410) or cerebrovascular events (ICD codes 430-438). Mortal outcomes had to be directly attributable to CVD as an underlying cause. The majority of CVD deaths were attributable to MI (ICD 410, 66.3%) and cerebrovascular disease (ICD 430-438, 14.5%) with the remaining 19.2% attributable to other forms of CVD (ICD 428-429, 440, 451). Specifically, these deaths were attributable to congestive heart failure, atherosclerosis, thrombophlebitis, and ill-defined heart disease. Sudden deaths were attributed to MI unless specific information was available that indicated another cause. The determination of event types was based on interpretations of hospital and death records by the nurse clinician and research epidemiologist, and in all questionable diagnoses, the final diagnosis was provided by the program physician (M.H.A.). Collectively, these are referred to as the cumulative incidence of CVD morbidity and mortality through June 1986. In subjects with multiple events, only the first event was included for analysis regardless of whether it was morbid or mortal. The only exception was in the three instances where a stroke or MI occurred shortly (within 3 months) before a CVD death. In these cases the mortal event was used for analysis. Data on length of follow-up to the last revisit, eventual dropout status, hospitalization, and final mortality status for CVD-related events are also available. Data are recorded on computer-compatible forms and processed for computer storage and analysis.
Statistical Methods
Summary descriptive statistics were calculated and univariate analyses performed, stratified by race, sex, age groupings at entry (less than 55 vs. 55 or more years), and BP strata (systolic: less than 160, 160-179, 180 or more mm Hg; diastolic: less than 95, 95-104, 105 or more mm Hg). Age 55 was used to separate older and younger subjects for analysis because it was close to the median age for the combined black and white worksite population. Event rates were computed for CVD and all-cause mortality and expressed per 1,000 person years of observation.
Years of potential life lost (YPLL) before age 65, a measure of premature mortality, was used to detect differences in mortality trends (from CVD and other causes) between the younger and older subjects. YPLL provides a better depiction of premature mortality by weighting deaths occurring at younger ages more heavily than those at older ages. 12 Given the variable lengths of follow-up from first revisit to last revisit before the event, or until the cutoff date for analyses, survival analysis techniques (Life Tables and Cox proportional hazards regression) were used. 13 -15 These techniques permit ready visualization of plotted event functions over time and enable multiple independent comparisons for model-fitting and testing purposes. The Cox regression procedure also allows parameter estimates calculated within each of the three entry DBP or SBP stratum before hypotheses are tested for the joint significance of BP subsets. An analysis of time to event occurrence was then performed. Significant independent contributions to the model by various covariates tested were identified by exami- nation of the regression coefficients and asymptomatic standard errors. Table 1 shows the baseline characteristics of blacks and whites at entry to the worksite program. Blacks were more likely than whites to smoke (current or quit within 5 years) (p<0.001), to have any ECG abnormality or, specifically, left ventricular hypertrophy (LVH) (p<0.0001), and to have a higher average DBP reading at entry (/?<0.0001). Blacks were also more likely to belong to the building maintenance union that includes primarily less skilled workers (/?<0.0001) than the other union groups. However, there were fewer black men (p<0.0001), and blacks were younger (p<0.0001), less likely to have elevated cholesterol levels (260 mg% or higher) (p<0.0001), and less likely to have been treated for hypertension before entering this program (p<0.0l) than whites. But when the proportions of blacks and whites receiving treatment at baseline were examined at each level of entry SBP and DBP, the differences by percent treated before entering the program was no longer significant.
Results
Initial Characteristics of Patients
Further investigation revealed that, among those not receiving treatment at entry (Table 2) , blacks were more likely to have been aware of their hypertension (p<0.001) and to have consulted a physician because of it (p<0.05). This was true at every age. 
Course in Therapy
The median duration of follow-up in the worksitebased program was 42 months for both blacks and whites, with those dropping from the program having shorter periods of participation than those still in the program (dropped, blacks 30 and whites 32 months; stayed, blacks 53 and whites 51 months). The mean annual dropout rate was similar for both racial groups (blacks 8.4% and whites 8.8%). When those who left the program were compared with those who stayed by their entry characteristics (age, sex, BP, smoking status, cholesterol, history of CVD, and prior treatment status), no significant differences were observed across racial groups. Furthermore, when the vital status of participants who left the program were examined (within 6 months of leaving), only 4 of 629 black and 1 of 1,292 white deaths were observed.
Blacks and whites responded to treatment with similar mean reductions in BP between initial and last revisits (Table 3) , which resulted in both groups achieving normal levels. However, the proportions of subjects achieving BP control (less than 160/95 mm Hg) were 69.8% (blacks) and 77.8% (whites), respectively (p<0.0001).
Health Outcomes: Univariate Analyses
The distribution of deaths was very similar to that seen in the general population of the United States, with CVD and cancer deaths heading the list (about 60% and 23% of total deaths, respectively). When all-cause mortality and cause-specific incidence rates were calculated for morbid and mortal cerebrovascular disease and MI (Table 4) , deaths from all causes did not differ significantly between the two racial groups (8.4 and 6.5 per 1,000 person years, respectively, for whites and blacks). Stroke incidence was also very similar across race, but the MI Ratio of myocardial infarction to strokes. On further investigation, there was a ratio of 14 heart attacks to every stroke (14 Mis vs. one stroke) occurring among black men entering the program before age 55 compared with a ratio of only 2.4 to 1 among whites (12 Mis vs. five strokes). For those entering at age 55 or older, this gap in the ratio had narrowed. Among black men, there were two Mis for every stroke (13 Mis vs. seven strokes) and for white men, three Mis for each stroke (63 Mis vs. 19 strokes). Thus, black men aged less than 55 years at entry had a higher risk of MI than of stroke, although older white men were still at greatest overall risk.
Interactive effect of age, sex, and race. The major difference in CVD incidence between blacks and whites was among older (age 55 years or greater at entry) men, with white men having an incidence of 20.8/1,000 person years and black men 11.5/1,000 person years (p<0.02) (Figure 2 ). The single, most important cause of this difference was MI occurrence (white men, 15.6 and black men, 7.5/1,000 person years, p<0.025).
Life Table analysis . Kaplan-Meier survival curves were plotted to compare the distribution of events by race, over time of follow-up (Figure 3) . The plot demonstrates that whites were at a greater disadvantage 16 (/><0.05) and that, over time, there was a tendency for the black advantage to increase. A similar racial pattern was observed when survival curves were plotted by smoking status at baseline.
Premature mortality from cardiovascular disease. Estimates of YPLL, 1718 based on 2,460 whites and 1,600 blacks entering the program before age 65, were calculated from the time of death to age 65. Despite a lower rate of events overall, the burden of CVD deaths among the young was greater for blacks (Table 5) . Overall, blacks lost 154.4 years compared with 95.1 years lost by whites, most of which was explained by CVD deaths. 
Health Outcomes: Multivariate Analyses
Results of a Cox proportional hazards regression (Table 6) provide the best predictive model of an adverse outcome among both black and white hypertensive patients, after we adjusted for entry DBP strata and controlled for possible or known confounders and effect modifiers, in addition to race. The interaction term between race and age at entry was found, after gender, to be the most powerful predictor of CVD, indicating that white hypertensive patients who entered the program at age 55 or older were at greatest risk of an event developing (/7=0.003). Cigarette smoking, treatment for hypertension at the time of entry into this program, and an abnormal ECG reading, were also significantly predictive of outcome (p values ranging from 0.015 to 0.004). The contribution to the model of higher serum cholesterol (p=0.025), greater body mass index (p =0.046), and a history of CVD (p=0.05) were either small or of less significance. The union to which the participant belonged (a factor introduced to control for possible socioeconomic differences) was not significantly related to outcome. A comparison of the hazard rates between the two races, adjusted simultaneously for all previous covariates other than the interaction term, showed whites to be 1.6 times more likely than blacks to have developed an event (p=0.007). Alternative 15 Union affiliation was partitioned into two categories: skilled (retail, typographers, truckers, carpenters, operating engineers, electricians) or nonskilled (building maintenance, construction).
Treated at entry, group treated for hypertension before entering program; ECG, electrocardiography.
parameterizations of race, such as interactions between cholesterol or smoking with race, did not improve the model. Similar results were found when the above steps were repeated after initial adjustment for entry SBP strata.
Discussion
The purpose of this study was to investigate whether, at the same level of entry blood pressure, both black and white participants in a worksite hypertension treatment program differed either in terms of blood pressure response to treatment or in subsequent cardiovascular morbidity and mortality.
The principal findings were, first, that BP response to treatment was essentially equivalent for blacks and whites. Specifically, the change in BP between initial and final revisits was indistinguishable, although blacks were less likely to have achieved BP control. Second, whites overall experienced significantly greater CVD morbidity and mortality than did blacks. Furthermore, when CVD incidence according to entry BP was examined, it was found that, at equivalent BP levels, risk for CVD among whites exceeded that of blacks. Even after adjustment for baseline differences in ECG abnormalities, smoking, DBP, serum cholesterol, body mass index, history of CVD at entry, and union of membership, the racial disparity persisted. This greater white CVD incidence was largely accounted for by MI among older white males. By contrast, stroke incidence was low and occurred at similar frequencies in both groups.
The striking finding that strokes, traditionally more common among blacks (particularly hypertensive blacks), occurred with equal frequency among blacks and whites, may reflect the fact that the primary benefit of BP management is in the prevention of stroke. 19 -22 Most clinical trials, however, involved predominantly white populations. In the Medical Research Council Trial (MRC), for example, the stroke rate was 1.4 per 1,000 patient years. The Hypertension Detection and Follow-Up Program (HDFP) did include blacks and whites and, although HDFP had somewhat different entry criteria, "stepped-care" (experimental) subjects were similar in many respects to the current study group. They enjoyed systematic, categorical, and free care for hypertension, designed to enhance adherence to therapy. In these circumstances, blacks and whites of both sexes in the stepped-care group had a lower stroke incidence than their counterparts in the referred care group, thus demonstrating the effectiveness of the treatment of hypertension for blacks as well as whites. Nevertheless, black men in the stepped-care group had a stroke rate (age-adjusted to its total sample) of 6.22/1,000 person years, whereas white males experienced only 2.85 events/1,000 person years. 23 The stroke rate in our study was low for both black and white men (1.6 blacks vs. 3.3 whites/ 1,000 person years, respectively, NS).
There is no clear explanation for the impressively low stroke experience among black men in this program when compared with participants in the HDFP stepped-care group. It may be because the HDFP sample was drawn from the community at large in contrast to the present study, which was limited to employed persons. However, if the difference was the "healthy worker effect" alone, it would be hard to explain the far greater expression among blacks than whites. HDFP investigators suggested that hypertension of longer duration might have been a factor in explaining the higher stroke rate among blacks. They defined prolonged hypertension on the basis of whether the patient was treated at entry or had electrocardiographic evidence of end-organ damage (such as left ventricular hypertrophy). In this worksite population such factors provided conflicting clues. White patients were actually more likely than blacks to be receiving treatment at entry, whereas blacks were more likely to have had left ventricular hypertrophy at entry. Thus, no consistent evidence for a difference in duration of disease between blacks and whites exists.
Perhaps socioeconomic differences between both black and white HDFP participants accounted for the higher stroke rate in blacks found in that study. Among these employed New Yorkers, socioeconomic differences were at least muted. Income levels were not available here and educational level only for subjects who entered the program after 1981. When educational level was examined in relation to union membership, we found that there was a significant association between the two and have thus used union membership as a surrogate measure to control for socioeconomic differences. The principal union affiliation of this patient population is derived from building maintenance, retail, skilled workers, and construction, in that order. As expected, CVD events were concentrated among the single largest group of unions, namely, building maintenance. However, the ethnic breakdown by event status did differ according to occupational affiliation: 48.7% of whites belonged to this union (compared with 68.6% blacks) but the CVD rate was 11.4 (whites) vs. 5.6 (blacks)/l,000 patient years, respectively (/><0.025). Nevertheless, as the results of the Cox analysis subsequently snowed, union affiliation was not a significant predictor of CVD outcome.
In contrast to stroke, clinical trials have not consistently shown a significant impact of BP control on occurrence of MI.
24 -27 Thus, it was not surprising that the primary difference between both black and white hypertensive patients in the present study was that older white men had greater MI morbidity and mortality than blacks at the same level of entry BP, despite fewer blacks achieving BP control at their last revisit. A review of the literature provides some support for the view that coronary artery disease incidence could have been expected to be lower in blacks than whites. The Veterans Administration study 20 on treatment results in men with initial DBP averaging 90-114 mm Hg reported a lower (10.5% vs. 12.7%) proportion of morbid events, predominantly coronary artery disease, in blacks than in nonblacks. Hence, if blood pressure treatment had scant impact on MI incidence, the natural advantage of blacks could help account for the present findings.
For example, a population-based study in Evans County, a rural Georgia community, specifically investigated ischemic heart disease incidence in a biracial community. An examination of 20-year mortality among three race-socioeconomic status (SES) groups in this population, found that ischemic heart disease was lowest in blacks (8.1/1,000 person years) and highest in whites of low SES (10.2/1,000 person years). 30 -31 Furthermore, when 20 -year all-cause mortality among men who were hypertensive at entry (1960) was analyzed, survival (adjusted for age, SBP, cholesterol, smoking, and Quetelet index) was worst for low SES white men. Moreover, in Charleston, South Carolina, the prevalence of CHD in 1960-1961 was higher in white men than black men, and the incidence of CHD and MI in white men was also higher than black men (1960-1961 through 1974-1975 ) among those free from disease at study inception. 32 Finally, in a 5-year follow-up study of men screened for the Multiple Risk Factor Intervention Trial, black men also had lower CHD death rates (4.6/1,000 person years) than white men (5.2/1,000 person years). 33 In nonhypertensive men (DBP less than 90 mm Hg), the relative risk of CHD (black vs. white) was 1.15, but this was reversed for hypertensive men (DBP 90 mm Hg or more), where blacks had the advantage with a relative risk of 0.69. In both cases, adjust-ment was made for age, serum cholesterol concentration, and cigarettes smoked per day.
The black advantage in regard to CHD may be due to lower serum cholesterol and perhaps higher high density lipoprotein (HDL) levels. 34 Miller et al 35 found an inverse relation between plasma HDL cholesterol and CHD risk in Jamaica, with the rural, black male sample having higher HDL concentrations than the urban, white male sample. Insufficient HDL determinations in the present study prevent assessment of its influence here. It should be noted, however, that whites were more likely than blacks to have cholesterol levels of 260 mg% or higher at entry, although cholesterol levels did not seem to be relevant to ultimate outcomes in this study.
Although CVD at equivalent entry BP levels overall was greater for whites than blacks in this worksite study, blacks experienced a higher rate of premature CVD mortality as reflected by a greater number of years of potential life lost before age 65. Although the US statistics for 1982 12 show a lower YPLL from all causes (99.2 years/1,000 population for blacks and 53.6 for whites), the direction of the difference is similar. Since more blacks have entered the program untreated, even though they were more likely to have been aware of their hypertension and to have consulted a physician, it would seem that still greater efforts are needed to encourage physicians to create the conditions that encourage continued black participation in effective care.
Potential confounding influences seem unlikely to explain the findings here. For example, selective bias in ascertainment of end-points was not operative. Nurse investigation of possible morbid or mortal events was not influenced by race. Indeed, after being alerted to potential events by nurses who monitor clinic attendance, morbidity/mortality data ascertainment was subsequently performed by persons without attention to the patient's race. Although more whites than blacks have left the program by the cutoff date for analysis, four of the five deaths (in the 6 months after departure) were observed among blacks. However, the two proportions were too small to alter the difference in CVD rates or the similarity in the all-cause mortality rates between races. The close similarity between the distribution of causes of death in this population and that for the nation as a whole offers further assurance that the pattern of end-point determination was valid. Another extraneous explanation for the findings might have been different patterns of program participation, but here again both black and white program participants were appropriately reflective of the populations from which they were drawn, with similar drop-out rates, duration of participation, and frequency of clinic attendance. Finally, difference in drug prescription and use may have influenced outcomes. Before 1981, a standard protocol provided all patients initial therapy with hydrochlorothiazide, either methyldopa or propranolol as second, and hydralazine as third choice of drug therapy, except in cases of drug intolerance. After 1981, first-choice option was extended to include propranolol and, when possible, patients were randomly assigned to hydrochlorothiazide or to propranolol. Although patients of both races overall were more likely to begin treatment with a diuretic, no differences were found between racial groups when drug therapy (i.e., drug class) was examined at initial or final revisits. Furthermore, among patients with left ventricular hypertrophy at entry into the program, there were also no differences by drug class across race.
In summary, these findings suggest that blacks and whites respond equally well to effective hypotensive therapy, and at the same level of pretreatment blood pressure, blacks are certainly at no greater risk of CVD than whites. In fact, the data here suggest that the conventional higher stroke rate associated with hypertension in blacks can be eliminated by effective treatment. Moreover, perhaps because coronary heart disease occurrence is modestly if at all affected by antihypertensive therapy, the natural propensity of whites to a higher MI incidence persists despite effective treatment and may therefore explain the higher overall CVD incidence of whites compared with blacks. Since the experience here suggests that younger black men (in contrast to older black men) are least likely to obtain antihypertensive therapy in the general community but do respond satisfactorily to effective care, it would appear that reasonable efforts to reach young black Americans offer an important route through which investment in health care may produce substantial human benefit.
